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THE influence of roxithromycin (RXM) on the expres-
sion  of  co-stimulatory  molecules,  CD40,  CD80  and
CD86, was examined in vivo. When BALB/c mice were
immunized intraperitoneally with two doses of dini-
trophenylated ovalbumin (DNP-OVA) at 1 week inter-
vals,  intraperitoneal  administration  of  RXM  at
250 m g/kg once a day for 14 days strongly suppressed
IgE contents in sera obtained from mice 22 days after
the first immunization. In addition, RXM treatment of
mice suppressed endogenous IL–4 contents in aque-
ous spleen extracts, which were enhanced by DNP-
OVA immunization. We next examined the influence
of  RXM  on  co-stimulatory  molecule  expression  on
splenic  lymphocytes.  RXM  treatment  of  the  immu-
nized mice caused suppression of CD40 expression,
but  this  treatment  did  not  affect  CD80  and  CD86
expression.
Key  words:  Roxithromycin,  CD40,  Suppression,  Din-
trophenylated ovalbumin, Immunization, Mouse, In vivo
Introduction
Administration of macrolide antibiotics such as eryth-
romycin  and troleandomycin  can favourably modify
the  clinical  status  of  patients  with  inflammatory
diseases.1–3 Although investigation of the mechanisms
of improvement  has suggested that it  is not due to
anti-microbiological effects of the drugs, the precise
mechanisms are not well understood.4 –6
We have demonstrated that oral administration of
roxithromycin  (RXM) once a day for 21  days could
suppress  the  ability  of  lymphocytes  to  produce
several types of inflammatory cytokines such as IL–1,
IL–3 and IL–5 in response to mitogenic stimulation in
vivo and  in  vitro.6–9 Subsequently,  Eyrand10 and
Forsgren11 have  reported  that  macrolide  antibiotics
such  as  erythromycin,  troleandomycin  and  RXM
inhibited chemotaxis and generation of inflammatory
mediators from polymorphonuclear leukocytes when
the cells were cultured in vitro in  the presence of
macrolides.
It  is  generally  accepted  that  antigen-specific
immune responses are initiated after the collaboration
of  T-cells  with  antigen  presenting  cells  (APC).12
Recently,  it  has  been  found  that  an  optimal T-cell
activation requires another cell-to-cell interaction.12,13
The first signal transduction is due to the interaction
between T-cell receptor and major histocompatibility
complex  class  II  molecule  with  antigenic  determi-
nant.  The  second  signal  is  provided  by  the  direct
contacts of co-stimulatory molecules on T-cells with
their  ligands  on  APC.13,14 The  signal  through  the
binding of CD28/CTLA4  on T cells with its ligands,
CD80  and CD86  on APC  is  a  crucial co-stimulatory
pathway.12 –14 Furthermore, engagement of the B-cell
marker CD40 by its ligand CD40L is also recognized to
play  an  important  role  in  T-cell-dependent  isotype
switching to IgE.14,15
There is much evidence that expression of the co-
stimulatory  molecules  CD40,  CD80  and  CD86  on
peripheral  blood  leukocytes  from  patients  with
inflammatory  diseases  was  upregulated  compared
with normal subjects,16–18 suggesting the importance
of these molecules in the induction and the develop-
ment of the diseases. Therefore, the present study was
undertaken  to  answer  the  unresolved  questions
regarding  the  favourable  effects  of  macrolide  anti-
biotics  on  inflammatory  diseases  by  examining  the
influences  of  RXM  on  expression  of  co-stimulatory
molecules in mice.
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Mice
BALB/c male mice, 5 weeks of age, were purchased
from Charles River Japan Inc. (Atsugi, Japan).
Immunization
BALB/c  mice  were  immunized  by  intraperitoneal
injection of 5.0 m g/ml of dinitrophenylated ovalbumin
(DNP-OVA) absorbed on 4 mg Al(OH)3, and boosted
intraperitoneally with the same dose of antigen 7 days
later.
Drugs and treatment
RXM  was  kindly  donated  by  EISAI  Co.  Ltd  (Tokyo,
Japan) as a water insoluble pure powder. The agent
was  dissolved  in  methyl  alcohol  at  50 mg/ml  and
diluted  with normal saline so  as  to give 1.0 mg/ml.
This solution was then sterilized by passing through a
0.22 m m  filter  and  stored  at  4°C  until  used.  The
immunized mice were given 250 m g/kg/day of RXM
intraperitoneally for 14 days starting 7 days after the
first  immunization  and  the  non-immunized  mice
injected  with  the  same  dose  of  RXM  for  2  weeks.
Since our previous reports have shown that  admin-
istration  of  2%  alcohol  did  not  show  any  adverse
effects on mouse immune responses,6,7,9 the control
mice received saline in the same route.
Assay for serum total IgE
The  blood  was  obtained  from  the  mice  by  cardiac
puncture under ether anesthesia 22 days after the first
immunization. After clotting, the serum was obtained
and total serum IgE levels were measured by mouse
IgE  enzyme  immunoassay  kits  (YAMASA  Co.  Ltd,
Chiba, Japan) according to the manufacturer’s recom-
mended  procedures.  The  assay  was  performed  in
duplicate and the results were expressed as the mean
ng/ml ± SD of five individual mice.
Preparation of aqueous spleen extracts
The spleen was removed from mice killed under ether
anesthesia and stored in ice-cold PBS until processed.
The organ was homogenized in 0.5ml PBS in an ice-
cold  water  bath  for  3min  using  a  glass  tissue
homogenizer. The supernatant was obtained by cen-
trifugation of the homogenized materials at 10 000 g
for 1 h at 4°C and used for aqueous spleen extract.
Assay for IL–4
IL–4  concentration  in  aqueous  spleen  extract  was
assayed by commercially available mouse IL–4 ELISA
kit (GENZYME Corp., Cambridge, MA, USA) accord-
ing to the manufacturer’s recommended procedures.
The ELISA was done in duplicate and the results were
expressed as the mean pg/ml ± SD of five individual
mice.
Preparation of spleen cell suspension
The spleen was removed from mice killed under ether
anesthesia and pressed through a 60 gauge steel mesh
to give a single cell suspension. After centrifugation at
1000 r.p.m. for 10 min at 4°C, the pelleted cells were
treated  with  0.15 M Tris–0.75%  NH4Cl  solution  for
10 min to lyse red blood cells. After filtering through a
200 gauge steel mesh, the residual cells were washed
three times and suspended in PBS at a concentration
of 1 ´ 106 cells/ml.
Monoclonal antibodies (mAbs) and flow
cytometry
The mAbs used in this study were anti-mouse CD16/
CD32 mAb,  fluorescein  isothiocyanate  (FITC)-conju-
gated anti-mouse CD40 mAb (hamster IgM), phycoer-
ythrin  (PE)-conjugated  anti-mouse  CD80mAb
(hamster  IgG),  FITC-conjugated  anti-mouse
CD86 mAb  (rat  IgG2a). They  were  purchased  from
PharMingen  (San  Diego,  CA,  USA).  To  block  non-
specific adherence of antibodies to murine Fc recep-
tors,  spleen  cells  (1  ´ 106 )  were  incubated  with
1.0 m g  of  anti-mouse  CD16/CD32 mAb  for  5 min  at
4°C, washed, and then labelled with either anti-mouse
CD80, CD86, or CD40 for 20 min in an ice-cold water
bath. After  washing  once,  fluorescent  staining  was
analysed immediately by flow cytometry on a FACS-
can (Becton Dickinson, Mountain View, CA, USA). The
fluorescent  intensity  of  cells  was  expressed  as  the
mean ± SD of four different experiments. Spleen cells
were also stained with monoclonal immunoglobulin
isotype  standards  (FITC-conjugated  hamster  IgM
against trinitrophenol and PE-conjugated hamster IgG
against keyhole limpet haemocyanin) purchased from
PharMingen, and fluorescent staining was analysed in
a similar manner.
Statistical analysis
The  statistical  significance  of  the  difference  in  the
mean  values  between  two  groups  was  analysed  by
Mann–Whitney U test.
Results
Influence of RXM on IgE and IL–4 production
in mice
The  first  set  of  experiments  was  carried  out  to
examine  the  influence  of  RXM  on  IgE  and  IL–4
production in immunized mice. As shown in Table 1,
K. Kawazu et al.
40 Mediators of Inflammation · Vol 9 · 2000RXM  treatment  of  non-immunized  mice  did  not
caused changes of IgE and IL–4 levels: IgE and IL–4
contents  in  sera  and  aqueous  spleen  extracts  from
RXM-treated, non-immunized mice were nearly identi-
cal to those from saline-treated, non-immunized mice
(P > 0.05). On the other hand, RXM treatment caused
significant  suppression  of IgE  and IL–4 contents in
sera and extracts, which were enhanced by DNP-OVA
immunization. IgE levels in sera  from saline-treated,
immunized  mice  were  significantly  decreased  from
223.8  ±  14.3 ng/ml  to  72.4  ±  6.3 ng/ml  by  RXM
treatment (P < 0.001). IL–4 levels in the extracts were
also decreased from 81.5 ± 9.7pg/ml to 31.5 ± 5.7 pg/
ml by RXM treatment (P < 0.001).
Influence of RXM treatment on co-stimulatory
molecule expression on spleen cells in vivo
This study was designed to examine the influences of
RXM on various profiles of CD40, CD80 and CD86 to
be expressed on B-lymphocytes. In flow cytometry on
FACScan, we gated and analysed on the lymphocyte
position/population of scattered dots of spleen cells
in the display of computer. Figure 1 shows one typical
profile among results obtained in four experiments of
mice  immunized  and  non-immunized  by  DNP-OVA
antigen.  RXM  treatment  of  non-immunized  mice
scarcely  affected  the  expression  profiles  of  the  CD
molecules on the gated splenic lymphocytes (Fig. 1,
left).  In  immunized  mice,  however,  RXM  exerted
remarkable suppression of CD40 molecule expression
on  the  gated  lymphocyte  population,  which  was
enhanced  by  DNP-OVA  antigen  (Fig.  1,  right). The
fluorescent intensity of splenic lymphocytes prepared
from saline-treated mice was 670.8 ± 89.65 and that
from RXM-treated mice was 344.56 ± 52.48. On the
other hand, expression of CD80 and CD86 molecules
was  not  influenced  by  the  2-week  treatments  with
RXM (Fig. 1, right).
Discussion
Several studies have shown that macrolide antibiotics
can  favourably  influence  the  clinical  condition  of
certain  patients  with  allergic  diseases.1–3 Naturally,
much  efforts  have  been  done  to  understand  the
mechanisms  by which  macrolide antibiotics modify
the  clinical  status  of  allergic  diseases.4–7, 9–11 How-
ever, the precise mechanisms are not well defined.
There is much evidence that allergic diseases are
caused  by  IgE  antibodies  against  specific  allergens.
Ishizaka has described that the prevention or suppres-
sion of IgE antibody formation against allergens might
be  one  of  fundamental  treatment  of  allergic  dis-
eases.19 Therefore,  we  examined  the  influence  of
RXM on IgE production in vivo. The results obtained
(Table 1) clearly demonstrate that 2-week treatments
with RXM could suppress IgE production in actively
sensitized mice.
Previously,  we  found  that  RXM  significantly  sup-
pressed the enhancement of 3H-thymidine uptake by
human  peripheral  blood  leukocytes  induced  by  in
vitro stimulation  with T-cell  mitogen  (Concanavalin
A), but not with B-cell mitogens.7 We also reported
the  suppressive  activity  of  RXM  on  the  ability  of
T-cells to produce several types of cytokines including
IL–5 in vitro and in vivo.6 Although experimental and
clinical  data  show  that  IgE  synthesis  in  B-cells  is
dependent  on  a  complex  process  involving  several
cellular and molecular interactions,15,20 –22 there is a
established  concept  that  IL–4  secreted  by  T-cells,
especially Th2 type helper T-cells, is the most impor-
tant cytokine for IgE generation. Taken together, the
present results (Table 1) suggest that RXM treatment
inhibits in vivo IL–4 secretion in response to DNP-
OVA immunization and results in suppression of IgE
levels  in  immunized  mice.  This  suggestion  is  sup-
ported  by  the  finding  that  treatment  of  mice  with
RXM  significantly  inhibits  endogenous  IL–4  levels,
which were enhanced by DNP-OVA immunization.
There  are  circumstantial  evidences  that  allergen-
specific Th2 type helper T-cells play a pivotal role in
the  induction  and  development  of  many  allergic
diseases.23 –25 And  also,  optimal  T-cell  activation  is
recognized to require not only interaction between
antigen peptide bound to MHC molecules of APC and
the  T-cell  receptor,  but  also  additional  signals,  so-
called co-stimulation. A number of recent reports have
shown that ligation of CD28 on T-cells and CD80 or
CD86 on APC is essential for activation of Th2 type
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Table 1. Influence of roxithromycin (RXM) on IgE production and IL–4 appearance in BALB/c mice immunized with DNP-OVA
mixed with Al(OH)3
Type of mice examined Treatment IgE levels IL–4 levels
(ng/ml ± SD) (pg/ml ± SD)
Non-immunized Saline 3.9 ± 1.1 18.8 ± 3.5
RXM 4.0 ± 0.1* 14.1 ± 6.0*
Immunized Saline 223.8 ± 14.3 81.5 ± 9.7
RXM 72.4 ± 6.3** 31.5 ± 5.7**
Each result was expressed as the mean ± SD of five individual mice.
*Not significant when compared with saline-treated mice (P > 0.05).
**Significant when compared with saline-treated mice (P < 0.001).K. Kawazu et al.
42 Mediators of Inflammation · Vol 9 · 2000
FIG. 1. Influence of roxithromycin on expression of co-stimulatory molecules on spleen cells prepared from BALB/c mice.
Determination was done 24h after treatment. The data were analysed by overlay histograms (FL–1 or FL–2) of splenocyte
population gated on lymphocyte position in scattered dots (FSC and SSC). The figure shows a representative expression profile
of results obtained in four different experiments. [····], saline-treated control mice; [__], RXM-treated mice.
helper T-cell and production of IL–4.26,27 Additionally,
interaction between CD40 on activated B-cells and its
ligand  CD40L  on  T-cells  has  been  reported  as  an
important co-stimulatory signal for switch recombina-
tion  to  IgE  synthesis  in  the  presence  of  IL–4.
Therefore, we next examined the influence of RXM
on CD40, CD80 and CD86 expression on spleen cells.
The  present  results  clearly  showed  that  RXM  treat-
ment of mice strongly suppressed the expression of
CD40 co-stimulatory molecule enhanced by DNP-OVAimmunization,  suggesting  that  protective  effect  of
RXM against IgE hyper-production is associated with
its  suppressive  effect  on  co-stimulatory  molecule
expression.
Although the present  study may provide possible
mechanisms  by  which  macrolide  antibiotics  can
modify  favourably  the  clinical  condition  of  allergic
diseases, more in-depth analyses are needed to clarify
the mode of action of the agents in the diseases. For
example, there are research subjects concerning CD4
vs. CD8 expression in thymus and lymph node, and
sIgD  vs.  sIgM  expression  in  spleen  to  show  the
existence  of  mature  lymphocytes.  In  addition,  the
suppression mechanisms of RXM regarding syntheses
of  proteins  such  as  IL–4  and  CD40  molecules
examined here are not clear at present. However, FK–
506 and rapamycin, macrolide antibiotics, exert their
immunosuppressive effects by formation of complex
between immunophilin and agents which can inhibit
gene transcription.28,29 It is possible that RXM binds
to  immunophilin,  intracellular  binding  protein,  and
the complexes interferes gene transcription, resulting
in  inhibition  of  protein  synthesis.  Another  experi-
ments are also needed to clarify this point.
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